| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T1 |
0-83 |
Sentence |
denotes |
Anti-ulcer activity of a slow-release zinc complex, zinc monoglycerolate (Glyzinc). |
| T2 |
84-229 |
Sentence |
denotes |
A slow-release zinc complex, zinc monoglycerolate (ZMG) was examined for its potential gastroprotective activity in various gastric ulcer models. |
| T3 |
230-908 |
Sentence |
denotes |
These models comprised (a) oral or parenteral non-steroidal anti-inflammatory drugs (NSAIDs) given to rats whose gastrointestinal mucosa was pre-sensitized by prior development of arthritis, oleyl alcohol-induced inflammation and cold exposure, (b) oral ethanol (12.5-100%) with and without added 4% HCl, (c) intraperitoneal reserpine (5 mg kg-1) in arthritic and normal rats and in normal mice, (d) oral NSAIDs given to mice in which acid and pepsin production was stimulated by co-administration of intraperitoneal bethanechol chloride (5 mg kg-1) to enhance ulcer development, and (e) NSAIDs given to carrageenan-inflamed rats to determine effects of ZMG on paw inflammation. |
| T4 |
909-1123 |
Sentence |
denotes |
In these models, ZMG given orally was effective in preventing development of gastric lesions, except with propionic acid NSAIDs; the effective doses being apparently dependent on the severity of the mucosal injury. |
| T5 |
1124-1312 |
Sentence |
denotes |
In many of the models ZMG was superior to zinc sulphate and other zinc salts or metal ion complexes investigated but was slightly more effective or equipotent compared with zinc acexamate. |
| T6 |
1313-1367 |
Sentence |
denotes |
ZMG did not impair the anti-oedemic effects of NSAIDs. |
| T7 |
1368-1570 |
Sentence |
denotes |
ZMG is thus an effective agent in preventing ulcer development in a wide range of model systems and may be more effective than zinc salts because of the controlled slow-release of zinc from the complex. |
| T1 |
0-83 |
Sentence |
denotes |
Anti-ulcer activity of a slow-release zinc complex, zinc monoglycerolate (Glyzinc). |
| T2 |
84-229 |
Sentence |
denotes |
A slow-release zinc complex, zinc monoglycerolate (ZMG) was examined for its potential gastroprotective activity in various gastric ulcer models. |
| T3 |
230-908 |
Sentence |
denotes |
These models comprised (a) oral or parenteral non-steroidal anti-inflammatory drugs (NSAIDs) given to rats whose gastrointestinal mucosa was pre-sensitized by prior development of arthritis, oleyl alcohol-induced inflammation and cold exposure, (b) oral ethanol (12.5-100%) with and without added 4% HCl, (c) intraperitoneal reserpine (5 mg kg-1) in arthritic and normal rats and in normal mice, (d) oral NSAIDs given to mice in which acid and pepsin production was stimulated by co-administration of intraperitoneal bethanechol chloride (5 mg kg-1) to enhance ulcer development, and (e) NSAIDs given to carrageenan-inflamed rats to determine effects of ZMG on paw inflammation. |
| T4 |
909-1123 |
Sentence |
denotes |
In these models, ZMG given orally was effective in preventing development of gastric lesions, except with propionic acid NSAIDs; the effective doses being apparently dependent on the severity of the mucosal injury. |
| T5 |
1124-1312 |
Sentence |
denotes |
In many of the models ZMG was superior to zinc sulphate and other zinc salts or metal ion complexes investigated but was slightly more effective or equipotent compared with zinc acexamate. |
| T6 |
1313-1367 |
Sentence |
denotes |
ZMG did not impair the anti-oedemic effects of NSAIDs. |
| T7 |
1368-1570 |
Sentence |
denotes |
ZMG is thus an effective agent in preventing ulcer development in a wide range of model systems and may be more effective than zinc salts because of the controlled slow-release of zinc from the complex. |